Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 11, 2011, Pages 3493-3501

  Banaszewska, Beata ^a   Pawelczyk, Leszek ^a   Spaczynski, Robert Z ^a   Duleba, Antoni J ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMAX; METFORMIN; PRASTERONE SULFATE; SIMVACHOL; SIMVASTATIN; TESTOSTERONE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACNE; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIRSUTISM; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; ORGAN SIZE; OVARIAN VOLUME; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; FEMALE; HIRSUTISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, LDL; METFORMIN; POLYCYSTIC OVARY SYNDROME; SIMVASTATIN; TREATMENT OUTCOME;

EID: 80655137134     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0501     Document Type: Article

References (43)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749 (Pubitemid 38766360)
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84:4006-4011 (Pubitemid 30644187)
3. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434-2438
4. Nelson VL, Legro RS, Strauss 3rd JF, McAllister JM 1999 Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 13: 946-957 (Pubitemid 30645312)
5. Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss 3rd JF, McAllister JM 2000 Differential activity of the cytochrome P450 17α-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 85:2304-2311 (Pubitemid 32269260)
6. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA 2010 Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 95:2038-2049
7. Repaci A, Gambineri A, Pasquali R 2011 The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 335:30-41
8. Wild RA, Applebaum-Bowden D, Demers LM, Bartholomew M, Landis JR, Hazzard WR, Santen RJ 1990 Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgens. Clin Chem 36:283-289
9. Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174 (Pubitemid 19250404)
10. Kelly CC, Lyall H, Petrie JR, GouldGW,Connell JM, Sattar N 2001 Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453-2455 (Pubitemid 32545690)
11. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D 2006 Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21: 1426-1431 (Pubitemid 44445017)
12. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ 2004 Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 82(Suppl 3):1193-1197 (Pubitemid 39335938)
13. Kwintkiewicz J, Foyouzi N, Piotrowski P, Rzepczynska I, Duleba AJ 2006 Mevastatin inhibits proliferation of rat ovarian theca-interstitial cells by blocking the mitogen-activated protein kinase pathway. Fertil Steril 86(4 Suppl):1053-1058 (Pubitemid 44427812)
14. Rzepczynska IJ, Piotrowski PC, Wong DH, Cress AB, Villanueva J, Duleba AJ 2009 Role of isoprenylation in simvastatin-induced inhibition of ovarian theca-interstitial growth in the rat. Biol Reprod 81:850-855
15. Sokalska A, Piotrowski PC, Rzepczynska IJ, Cress A, Duleba AJ 2010 Statins inhibit growth ofhumantheca-interstitial cells inPCOS and non-PCOS tissues independently of cholesterol availability. J Clin Endocrinol Metab 95:5390-5394
16. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L 2006 Simvastatin improves biochemical parameters inwomenwith polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 85:996-1001
17. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ 2007 Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 92:456-461
18. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL 2009 The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 94:103-108
19. Kaya C, Pabuccu R, Cengiz SD, Dünder I 2010 Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: a prospective, randomized study. Exp Clin Endocrinol Diabetes 118:161-166
20. Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y 2010 Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, doubleblind, placebo-controlled study. Fertil Steril 94:2208-2213
21. Raja-Khan N, Kunselman AR, Hogeman CS, Stetter CM, Demers LM, Legro RS 2011 Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertil Steril 95:1849-1852
22. Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES, Atkin SL 2010 Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clin Chem 56:1696-1700
23. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ 2009 Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 94:4938-4945
24. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF 2006 Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91:4237-4245 (Pubitemid 44833391)
25. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society 2009 The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456-488
26. Ferriman D, Gallwey JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447
27. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L 2000 Metformin therapy improves hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73: 1149-1154 (Pubitemid 30336759)
28. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluationof simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666-3672 (Pubitemid 30645223)
29. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470 (Pubitemid 29418240)
30. Hughesdon PE 1982 Morphology and morphogenesis of the Stein- Leventhal ovary and of so called "hyperthecosis." Obstet Gynecol Surv 37:59-77 (Pubitemid 12104168)
31. Attia GR, Rainey WE, Carr BR 2001 Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 76:517-524
32. Mansfield R, Galea R, Brincat M, Hole D, Mason H 2003 Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 79:956-962 (Pubitemid 36385020)
33. Goldstein JL, Brown MS 1990 Regulation of the mevalonate pathway. Nature 343:425-430
34. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, Mach F 2005 Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 25:1231-1236 (Pubitemid 40776614)
35. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH 2006 Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome.Arandomized, placebo-controlled, double-blind multicentre study. Hum Reprod 21:80-89 (Pubitemid 41794294)
36. Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF 2007 Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 92:2453-2461
37. Banaszewska B, Duleba AJ, Spaczynski RZ, Pawelczyk L 2006 Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. Am J Obstet Gynecol 194:1266-1272
38. Lord J, Thomas R, Fox B, Acharya U, Wilkin T 2006 The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome-a randomised, doubleblind, placebo-controlled trial. BJOG 113:817-824 (Pubitemid 43961744)
39. Armitage J 2007 The safety of statins in clinical practice. Lancet 370:1781-1790 (Pubitemid 350137473)
40. Brown WV 2008 Safety of statins. Curr Opin Lipidol 19:558-562
41. Bełtowski J, Wójcicka G, Jamroz-Wioeniewska A 2009 Adverse effects of statins-mechanisms and consequences. Curr Drug Saf 4:209-228
42. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP 2010 Atorvastatin: safety and tolerability. Expert Opin Drug Saf 9:667-674
43. Edison RJ, Muenke M 2004 Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 131:287-298